Archived NCCN Tumor Boards: Managing Unique Toxicities and Immune-Related Adverse Effects of Treatment for Hodgkin Lymphoma

There has been a major shift in the treatment paradigm of advanced CHL within the last several years, with antibody-drug conjugates and immune checkpoint inhibitors becoming an integral part of front-line treatment, allowing for reduction in toxicities such as pulmonary toxicity associated with bleomycin and secondary cancer risk from agents such as procarbazine. This activity will help you navigate the unique toxicities of novel agents, such as peripheral neuropathy associated with brentuximab vedotin and immune-related adverse effects associated with immune checkpoint inhibitors. You will gain practical insights to the latest treatments and new approaches into patient care.   

Target Audience

This program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss key results of the SWOG S1826, ECHELON-1, and GHSG HD21 studies.
  • Describe how the treatment paradigm for advanced stage classic Hodgkin lymphoma has shifted in recent years. 
  • Identify unique toxicities of brentuximab vedotin (BV) and check point inhibitors (CPI) (e.g., nivolumab).

You may also be interested in

Recorded Presentation from Optimizing Patient Outcomes - New Primary Therapy Options for Stage III-IV Hodgkin Lymphoma

With the addition of two new regimens for the treatment of stage III-IV advanced Hodgkin lymphoma, it is important for the interprofessional oncology care team to be aware of new therapy recommendations in order to provide support by monitoring for drug interactions and adverse drug reactions, un
Novel Treatment Options for Hodgkin Lymphoma
Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Azurity Pharmaceuticals
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Novartis

This activity is supported by an independent medical education grant from AbbVie.

This activity is supported through an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
05/06/2026
Course expires: 
04/30/2027
Part of: 
Archived NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Ranjana H. Advani, MD
Stanford Cancer Institute
 
Chandley Silin, MSN, FNP-BC, AOCNP
Stanford Cancer Institute
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below have no financial relationship(s) with ineligible companies to disclose.
 
Chandley Silin, MSN, FNP-BC, AOCNP
 
The faculty listed below has the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
 
Ranjana H. Advani, MD
BeiGene: Grant/Research Support
Genentech, Inc.:  Scientific Advisor; Grant/Research Support
Genmab: Scientific Advisor
Gilead Sciences, Inc.: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor; Grant/Research Support
Pfizer Inc.: Scientific Advisor
Regeneron Pharmaceuticals, Inc.: Grant/Research Support
Roche Laboratories, Inc.: Scientific Advisor; Grant/Research Support
SeaGen: Grant/Research Support

NCCN Staff Disclosures
 
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
imageIn support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-040-H01-P

Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until April 30, 2027. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission to provide continuing education credit to CCM® Board-Certified Case Managers. The course is approved for 1.0 CE contact hour.  Activity Code: S00066887; Approval Number: 260000965
To claim these CEs, log into your dashboard at www.yourcommission.org.  

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing